Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_47_библиотеки_им_акад_М_И_Перельмана
.pdf
192
33. Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, et al. Innate immune
responses in hepatitis C virus-exposed healthcare workers who do not develop acute infec-
tion. Hepatology. 2013 Nov;58(5):1621–31.
34. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, etal. Natural killer cells are
polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.
Gastroenterology. 2010 Jan;138(1):325–35.e1-2.
35. Kramer B, Korner C, Kebschull M, Glassner A, Eisenhardt M, Nischalke HD, etal. Natural
killer p46High expression denes a natural killer cell subset that is potentially involved in
control of hepatitis C virus replication and modulation of liver brosis. Hepatology. 2012
Oct;56(4):1201–13.
36. Eisenhardt M, Glassner A, Kramer B, Korner C, Sibbing B, Kokordelis P, etal. The CXCR3(+)
CD56Bright phenotype characterizes a distinct NK cell subset with anti-brotic potential that
shows dys-regulated activity in hepatitis C.PLoS One. 2012;7(7):e38846.
37. Neumann-Haefelin C, Thimme R.Adaptive immune responses in hepatitis C virus infection.
Curr Top Microbiol Immunol. 2013;369:243–62.
38. Bartosch B, Dubuisson J, Cosset FL.Infectious hepatitis C virus pseudo-particles containing
functional E1-E2 envelope protein complexes. J Exp Med. 2003 Mar 3;197(5):633–42.
39. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, etal. Rapid induction
of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis
C.Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025–30.
40. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, etal. Cellular immune
responses persist and humoral responses decrease two decades after recovery from a single-
source outbreak of hepatitis C.Nat Med. 2000 May;6(5):578–82.
41. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, etal. Hepatitis C
virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet.
1994 Feb 12;343(8894):388–90.
42. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV per-
sistence and immune evasion in the absence of memory T cell help. Science. 2003 Oct
24;302(5645):659–62.
43. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, etal. Analysis
of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000
May 1;191(9):1499–512.
44. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV.Determinants of viral
clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001 Nov
19;194(10):1395–406.
45. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM.Suppression of HCV-
specic T cells without differential hierarchy demonstrated exvivo in persistent HCV infec-
tion. Hepatology. 2003 Dec;38(6):1437–48.
46. Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, etal.
Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary
infection and reinfection. J Clin Virol. 2006 May;36(1):24–31.
47. Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantication
and localisation of FOXP3+ T lymphocytes and relation to hepatic inammation during
chronic HCV infection. J Hepatol. 2007 Sep;47(3):316–24.
48. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, etal.
Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral
clearance in acute hepatitis C virus infection. Lancet. 1995 Oct 14;346(8981):1006–7.
49. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, etal. Different clinical
behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-
viral cell-mediated immune response. J Clin Invest. 1996 Aug 1;98(3):706–14.
50. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, et al.
Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus
infection. Gut. 2011 Nov;60(11):1563–71.
N. V. Bergasa
https://t.me/medicina_free
193
51. Neumann-Haefelin C, Thimme R.Success and failure of virus-specic T cell responses in
hepatitis C virus infection. Dig Dis. 2011;29(4):416–22.
52. Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, etal. Analysis of CD8+ T-cell-
mediated inhibition of hepatitis C virus replication using a novel immunological model.
Gastroenterology. 2009 Apr;136(4):1391–401.
53. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, etal. Regulatory T
cells suppress invitro proliferation of virus-specic CD8+ T cells during persistent hepatitis
C virus infection. J Virol. 2005 Jun;79(12):7852–9.
54. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, etal. Memory
CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp
Med. 2003 Jun 16;197(12):1645–55.
55. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, etal. Sustained dys-
function of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001
Jun;75(12):5550–8.
56. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M,
etal. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology.
2005 Oct;42(4):828–37.
57. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, etal. Functional res-
toration of HCV-specic CD8 T cells by PD-1 blockade is dened by PD-1 expression and
compartmentalization. Gastroenterology. 2008 June;134(7):1927–37.e1-2.
58. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, etal. PD-1 expression
in acute hepatitis C virus (HCV) infection is associated with HCV-specic CD8 exhaustion.
J Virol. 2006 Nov;80(22):11398–403.
59. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, et al. High-
programmed death-1 levels on hepatitis C virus-specic T cells during acute infection are
associated with viral persistence and require preservation of cognate antigen during chronic
infection. J Immunol. 2008 Dec 15;181(12):8215–25.
60. Abel M, Sene D, Pol S, Bourliere M, Poynard T, Charlotte F, etal. Intrahepatic virus-specic
IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.
Hepatology. 2006 Dec;44(6):1607–16.
61. http://www.who.int/mediacentre/factsheets/fs164/en/.
62. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD.The increasing burden of
mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med.
2012 Feb 21;156(4):271–8.
63. Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, etal. The spread
of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. Lancet
Infect Dis. 2016 June;16(6):698–702.
64. Yarnell S, Li L, MacGrory B, Trevisan L, Kirwin P.Substance use disorders in later life: a
review and synthesis of the literature of an emerging public health concern. Am J Geriatr
Psychiatry. 2020 Feb;28(2):226–36.
65. Geboy AG, Mahajan S, Daly AP, Sewell CF, Fleming IC, Cha HA, etal. High hepatitis C
infection rate among baby boomers in an urban primary care clinic: results from the HepTLC
initiative. Public Health Rep. 2016 May-Jun;131(Suppl 2):49–56.
66. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana
M, etal. Screening for hepatitis C virus infection in adolescents and adults: US preventive
services task Force recommendation statement. JAMA. 2020 Mar;323:970–5.
67. Alter MJ.HCV routes of transmission: what goes around comes around. Semin Liver Dis.
2011 Nov;31(4):340–6.
68. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
69. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of
antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and
chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–500.
6
Chronic Hepatitis C
https://t.me/medicina_free
194
70. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al.
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.
Gastroenterology. 2003 July;125(1):80–8.
71. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, etal. The natural
history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000 July
26;284(4):450–6.
72. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the
importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999
Mar;29(3):908–14.
73. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al.
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated
measurements of serum viral load. Hepatology. 2003 Jan;37(1):60–4.
74. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, etal. Outcome of an
outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics
studies. Hepatology. 2002 Oct;36(4 Pt 1):993–1000.
75. Poynard T, Bedossa P, Opolon P.Natural history of liver brosis progression in patients with
chronic hepatitis C. the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet.
1997 Mar 22;349(9055):825–32.
76. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, etal. The natural history
of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients.
Hepatology. 2006 June;43(6):1303–10.
77. Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, et al. Natural course of
chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos
study. Am J Gastroenterol. 2008 Sep;103(9):2248–53.
78. Albloushi SS, Murray FE, Callagy G, Courtney MG, O'Keane JC, Kay E.Changes in liver
histopathology in women infected with hepatitis C through contaminated anti-D immuno-
globulin injections in Ireland. Eur J Gastroenterol Hepatol. 1998 Jan;10(1):69–73.
79. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, etal. The natural course of
hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral
clearance and chronic HCV infection. Gut. 2001 Sep;49(3):423–30.
80. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, etal. Steatosis
affects chronic hepatitis C progression in a genotype specific way. Gut. 2004
Mar;53(3):406–12.
81. Konerman MA, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, etal. Fibrosis pro-
gression in human immunodeciency virus/hepatitis C virus coinfected adults: prospective
analysis of 435 liver biopsy pairs. Hepatology. 2014 Mar;59(3):767–75.
82. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated
anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999 Apr
22;340(16):1228–33.
83. Williams AL, Hoofnagle JH.Ratio of serum aspartate to alanine aminotransferase in chronic
hepatitis. Relationship to cirrhosis. Gastroenterology. 1988 Sep;95(3):734–9.
84. Nyblom H, Berggren U, Balldin J, Olsson R.High AST/ALT ratio may indicate advanced alco-
holic liver disease rather than heavy drinking. Alcohol Alcohol. 2004 Jul-Aug;39(4):336–9.
85. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for
laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease
Control and Prevention. MMWR Recommendations and reports : Morbidity and mortal-
ity weekly report Recommendations and reports/Centers for Disease Control. 2003 Feb
7;52(RR-3):1–13.
86. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, et al. Evaluation of a
new, rapid test for detecting HCV infection, suitable for use with blood or oral uid. J Virol
Methods. 2011 Mar;172(1–2):27–31.
87. http://www.fda.gov.
N. V. Bergasa
https://t.me/medicina_free
195
88. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The
natural history of community-acquired hepatitis C in the United States. The sentinel counties
chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–905.
89. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med.
2002 Sep 26;347(13):975–82.
90. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL.Health-related quality of life in chronic
hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.
Hepatology. 1999 Aug;30(2):550–5.
91. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, etal. Serum auto-
antibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the
disease prole. Hepatology. 1997 Sep;26(3):561–6.
92. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, Schiavon Lde L,
etal. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant
or an epiphenomenon? Eur J Gastroenterol Hepatol. 2009 Apr;21(4):440–6.
93. Chretien P, Chousterman M, Abd Alsamad I, Ozenne V, Rosa I, Barrault C, etal. Non-organ-
specic autoantibodies in chronic hepatitis C patients: association with histological activity
and brosis. J Autoimmun. 2009 May-Jun;32(3–4):201–5.
94. Marconcini ML, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon L, Narciso-
Schiavon JL.Autoantibody prole in individuals with chronic hepatitis C.Rev Soc Bras Med
Trop. 2013 Mar-Apr;46(2):147–53.
95. Mauss S, Berger F, Schober A, Moog G, Heyne R, John C, etal. Screening for autoantibodies
in chronic hepatitis C patients has no effect on treatment initiation or outcome. J Viral Hepat.
2013 Apr;20(4):e72–7.
96. Schmid M, Pirovino M, Altorfer J, Gudat F, Bianchi L.Acute hepatitis non-A, non-B; are
there any specic light microscopic features? Liver. 1982 Mar;2(1):61–7.
97. Kryger P, Christoffersen P.Light microscopic morphology of acute hepatitis non-A, non-
B.A comparison with hepatitis type A and B.Liver. 1982 Sep;2(3):200–6.
98. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM.The pathology of hepatitis
C.Hepatology. 1992 Apr;15(4):567–71.
99. Gerber MA, Krawczynski K, Alter MJ, Sampliner RE, Margolis HS.Histopathology of com-
munity acquired chronic hepatitis C. the sentinel counties chronic non-A, non-B Hepatitis
Study Team. Mod Pathol. 1992 Sep;5(5):483–6.
100. Roberts JM, Searle JW, Cooksley WG.Histological patterns of prolonged hepatitis C infec-
tion. Gastroenterol Jpn. 1993 May;28(Suppl 5):37–41.
101. Poulsen H, Christoffersen P.Abnormal bile duct epithelium in liver biopsies with histological
signs of viral hepatitis. Acta Pathol Microbiol Scand. 1969;76(3):383–90.
102. Vyberg M. Diverticular bile duct lesion in chronic active hepatitis. Hepatology. 1989
Nov;10(5):774–80.
103. Mosnier JF, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou JP.The intraportal lym-
phoid nodule and its environment in chronic active hepatitis C: an immunohistochemical
study. Hepatology. 1993 Mar;17(3):366–71.
104. Walewska-Zielecka B, Madalinski K, Jablonska J, Godzik P, Cielecka-Kuszyk J, Litwinska
B.Composition of inammatory inltrate and its correlation with HBV/HCV antigen expres-
sion. World J Gastroenterol WJG. 2008 July 7;14(25):4040–6.
105. Zhang L, Zhao Y.The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells:
multiple pathways on the road. J Cell Physiol. 2007 Jun;211(3):590–7.
106. de Goer de Herve MG, Jaafoura S, Vallee M, Taouk Y. FoxP3(+) regulatory CD4 T cells
control the generation of functional CD8 memory. Nat Commun. 2012;3:986.
107. Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A.Abundant numbers of
regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the
extent of brosis. J Hepatol. 2010 Mar;52(3):315–21.
6
Chronic Hepatitis C
https://t.me/medicina_free
196
108. Langhans B, Kramer B, Louis M, Nischalke HD, Huneburg R, Staratschek-Jox A, et al.
Intrahepatic IL-8 producing Foxp3(+)CD4(+) regulatory T cells and brogenesis in chronic
hepatitis C.J Hepatol. 2013 Aug;59(2):229–35.
109. Sturm N, Thelu MA, Camous X, Dimitrov G, Ramzan M, Dufeu-Duchesne T, et al.
Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogen-
esis. J Hepatol. 2010 Jul;53(1):25–35.
110. Goodman ZD, Ishak KG.Histopathology of hepatitis C virus infection. Semin Liver Dis.
1995 Feb;15(1):70–81.
111. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, etal. Prognostic value of
liver brosis biomarkers: a meta-analysis. Gastroenterol Hepatol. 2011 July;7(7):445–54.
112. Asselah T, Marcellin P, Bedossa P.Improving performance of liver biopsy in brosis assess-
ment. J Hepatol. 2014 Aug;61(2):193–5.
113. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, etal. Extrahepatic
manifestations associated with hepatitis C virus infection. A prospective multicenter study
of 321 patients. The GERMIVIC.Groupe d’Etude et de Recherche en Medecine Interne et
Maladies Infectieuses sur le Virus de l’Hepatite C.Medicine. 2000 Jan;79(1):47–56.
114. Yamada S, Mine S, Fujisaki T, Ohnari N, Eto S, Tanaka Y.Hepatic sarcoidosis associated
with chronic hepatitis C.J Gastroenterol. 2002;37(7):564–70.
115. Bonnet F, Morlat P, Dubuc J, De Witte S, Bonarek M, Bernard N, etal. Sarcoidosis-associated
hepatitis C virus infection. Dig Dis Sci. 2002 Apr;47(4):794–6.
116. Sanchez MJ, Bergasa NV. Hepatitis C associated cardiomyopathy: potential pathogenic
mechanisms and clinical implications. Med Sci Monitor. 2008 May;14(5):RA55–63.
117. Matsumori A, Matoba Y, Sasayama S.Dilated cardiomyopathy associated with hepatitis C
virus infection. Circulation. 1995 Nov 1;92(9):2519–25.
118. Matsumori A, Ohashi N, Nishio R, Kakio T, Hara M, Furukawa Y, etal. Apical hypertrophic
cardiomyopathy and hepatitis C virus infection. Jpn Circ J. 1999 Jun;63(6):433–8.
119. Matsumori A.Hepatitis C virus and cardiomyopathy. Herz. 2000 May;25(3):249–54.
120. Prati D, Poli F, Farma E, Picone A, Porta E, De Mattei C, etal. Multicenter study on hepatitis
C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program
(NITP). J Med Virol. 1999 Jun;58(2):116–20.
121. Reis FJ, Viana M, Oliveira M, Sousa TA, Parana R.Prevalence of hepatitis C and B virus
infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study. Braz J
Infect Dis. 2007 Jun;11(3):318–21.
122. Boyella V, Onyebueke I, Farraj N, Graham-Hill S, El Younis C, Bergasa NV. Prevalence
of hepatitis C virus infection in patients with cardiomyopathy. Ann Hepatol. 2009
Apr-Jun;8(2):113–5.
123. Ramos-Casals M, Stone JH, Cid MC, Bosch X.The cryoglobulinaemias. Lancet. 2012 Jan
28;379(9813):348–60.
124. Tedeschi A, Barate C, Minola E, Morra E. Cryoglobulinemia. Blood Rev. 2007
Jul;21(4):183–200.
125. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, etal. Association between
hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol. 1991
Nov-Dec;9(6):621–4.
126. Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, etal. Non-enveloped HCV
core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed
cryoglobulinaemia. Clin Exp Immunol. 2003 Aug;133(2):275–82.
127. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, etal. Cryoglobulinemia in
chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994
May;106(5):1291–300.
128. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova
RP, etal. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and
association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol WJG. 2007
Dec 28;13(48):6518–28.
N. V. Bergasa
https://t.me/medicina_free
197
129. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, etal. Binding of hepatitis
C virus to CD81. Science. 1998 Oct 30;282(5390):938–41.
130. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR.Clonal B-cell expan-
sions in peripheral blood of HCV-infected patients. Br J Haematol. 1995 Jul;90(3):548–52.
131. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of
non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with
hepatitis C virus. JAMA. 2007;297(18):2010–7.
132. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid
neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prevent.
2006 Nov;15(11):2078–85.
133. Ruhl CE, Menke A, Cowie CC, Everhart JE.The relationship of Hepatitis C virus infection
with diabetes in the United States population. Hepatology. 2014 Feb 5;60(4):1139–49.
134. Ryan Caballes F, Sendi H, Bonkovsky HL.Hepatitis C, porphyria cutanea tarda and liver
iron: an update. Liver Int. 2012 July;32(6):880–93.
135. Hussain I, Hepburn NC, Jones A, O’Rourke K, Hayes PC.The association of hepatitis C viral
infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol.
1996 Jul;21(4):283–5.
136. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, etal.
Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology.
1998 Jun;27(6):1661–9.
137. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus
infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003
Oct;39(4):620–7.
138. Jalil S, Grady JJ, Lee C, Anderson KE.Associations among behavior-related susceptibility
factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010 Mar;8(3):297–302.
139. Kauppinen R.Porphyrias. Lancet. 2005 Jan;365(9455):241–52.
140. Danton M, Lim CK.Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis
by high-performance liquid chromatography/electrospray ionization tandem mass spectrom-
etry. Biomed Chromatogr BMC. 2007 Jul;21(7):661–3.
141. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP.A porphomethene inhibitor
of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S
A. 2007 Mar 20;104(12):5079–84.
142. Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case-
control study and meta-analysis of the literature. J Am Acad Dermatol. 1999 Jul;41(1):31–6.
143. O’Reilly FM, Darby C, Fogarty J, O’Moore R, Courtney MG, O’Connor J, etal. Porphyrin
metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed. 1996
Feb;12(1):31–3.
144. Haque S, Chandra B, Gerber MA, Lok AS.Iron overload in patients with chronic hepatitis C:
a clinicopathologic study. Hum Pathol. 1996 Dec;27(12):1277–81.
145. Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, etal. Hepcidin expres-
sion in the liver: relatively low level in patients with chronic hepatitis C.Mol Med. 2007
Jan–Feb;13(1–2):97–104.
146. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection,
mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013 Apr;61(4):623–37.
147. Garcia-Valdecasas J, Bernal C, Garcia F, Cerezo S, Umana WO, von Albertini B, etal.
Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol
JASN. 1994 Aug;5(2):186–92.
148. Fabrizi F, Lunghi G, Messa P, Martin P.Therapy of hepatitis C virus-associated glomerulone-
phritis: current approaches. J Nephrol. 2008 Nov–Dec;21(6):813–25.
149. Fabrizi F. Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence. Scientica.
2012;2012:128382.
150. Fornasieri A, Armelloni S, Bernasconi P, Li M, de Septis CP, Sinico RA, etal. High bind-
ing of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular
6
Chronic Hepatitis C
https://t.me/medicina_free
198
bronectin: a mechanism for induction of in situ immune complex glomerulonephritis? Am J
Kidney Dis. 1996 Apr;27(4):476–83.
151. Roy K, Bagg J. Hepatitis C virus and oral disease: a critical review. Oral Dis. 1999
Oct;5(4):270–7.
152. Jorgensen C, Legouffe MC, Perney P, Coste J, Tissot B, Segarra C, etal. Sicca syndrome
associated with hepatitis C virus infection. Arthritis Rheum. 1996 Jul;39(7):1166–71.
153. Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R, etal. Extrahepatic
manifestations of chronic hepatitis C infection and the interrelationship between pri-
mary Sjogren’s syndrome and hepatitis C in Swedish patients. J Intern Med. 1999
Feb;245(2):127–32.
154. Ramos-Casals M, Garcia-Carrasco M, Cervera R, Rosas J, Trejo O, de la Red G, et al.
Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immuno-
logic description of 35 cases. Medicine. 2001 Jan;80(1):1–8.
155. Loustaud-Ratti V, Riche A, Liozon E, Labrousse F, Soria P, Rogez S, etal. Prevalence and
characteristics of Sjogren’s syndrome or Sicca syndrome in chronic hepatitis C virus infec-
tion: a prospective study. J Rheumatol. 2001 Oct;28(10):2245–51.
156. Coll J, Gambus G, Corominas J, Tomas S, Esteban JI, Guardia J. Immunohistochemistry
of minor salivary gland biopsy specimens from patients with Sjogren’s syndrome with and
without hepatitis C virus infection. Ann Rheum Dis. 1997 Jun;56(6):390–2.
157. Toussirot E, Le Huede G, Mougin C, Balblanc JC, Bettinger D, Wendling D.Presence of
hepatitis C virus RNA in the salivary glands of patients with Sjogren’s syndrome and hepati-
tis C virus infection. J Rheumatol. 2002 Nov;29(11):2382–5.
158. Sharma A, Bialynicki-Birula R, Schwartz RA, Janniger CK.Lichen planus: an update and
review. Cutis. 2012 Jul;90(1):17–23.
159. Jubert C, Pawlotsky JM, Pouget F, Andre C, DeForges L, Bretagne S, etal. Lichen planus and
hepatitis C virus—related chronic active hepatitis. Arch Dermatol. 1994 Jan;130(1):73–6.
160. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, et al.
Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.
Hepatology. 1994 Apr;19(4):841–8.
161. Lodi G, Pellicano R, Carrozzo M.Hepatitis C virus infection and lichen planus: a systematic
review with meta-analysis. Oral Dis. 2010 Oct;16(7):601–12.
162. Shengyuan L, Songpo Y, Wen W, Wenjing T, Haitao Z, Binyou W. Hepatitis C virus and
lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol. 2009
Sep;145(9):1040–7.
163. Bergasa NV, Holguin GE, Martinez M, Chen YL, Baumstein D.Adrenal tumors in patients
with chronic hepatitis C.Gastroenterol Hepatol. 2010 Jun;6(6):385–7.
164. Singla M, Sy A, Baumstein D, Kadeishvili K, Matari HM, Bergasa N.Chronic Hepatitis C is
associated with adrenal tumors. J Gastroenterol Hepatol Res. 2013;2(7):680–2.
165. Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, et al. Hepatitis C virus may
infect extrahepatic tissues in patients with hepatitis C.World J Gastroenterol WJG. 2000
Dec;6(6):805–11.
166. Okan A, Comlekci A, Akpinar H, Okan I, Yesil S, Tankurt E, etal. Serum concentrations of
insulin-like growth factor-I and insulin-like growth factor binding protein-3in patients with
chronic hepatitis. Scand J Gastroenterol. 2000 Nov;35(11):1212–5.
167. Penhoat A, Chatelain PG, Jaillard C, Saez JM.Characterization of insulin-like growth factor
I and insulin receptors on cultured bovine adrenal fasciculata cells. Role of these peptides on
adrenal cell function. Endocrinology. 1988 Jun;122(6):2518–26.
168. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The
unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med.
2020 Jul 7;173(1):10–20.
169. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, etal. A long-term study of hepatitis C
virus replication in non-a, non-B hepatitis. N Engl J Med. 1991 Jul 11;325(2):98–104.
N. V. Bergasa
https://t.me/medicina_free
199
170. Liang TJ, Ghany MG.Therapy of hepatitis C--back to the future. N Engl J Med. 2014 May
22;370(21):2043–7.
171. Chung RT, Baumert TF.Curing chronic hepatitis C—the arc of a medical triumph. N Engl J
Med. 2014 Apr 24;370(17):1576–8.
172. Panel A-IHG. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations
for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018 Oct
30;67(10):1477–92.
173. Terrault NA. Care of patients following cure of Hepatitis C virus infection. Gastroenterol
Hepatol (N Y). 2018 Nov;14(11):629–34.
174. Feld JJ, Hoofnagle JH.Mechanism of action of interferon and ribavirin in treatment of hepa-
titis C.Nature. 2005 Aug 18;436(7053):967–72.
175. Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med. 2009 Apr
30;360(18):1899–901.
176. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, etal. A sustained
virologic response is durable in patients with chronic hepatitis C treated with peginterferon
alfa-2a and ribavirin. Gastroenterology. 2010 Nov;139(5):1593–601.
177. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, etal. Ribavirin
as therapy for chronic hepatitis C. a randomized, double-blind, placebo-controlled trial. Ann
Intern Med. 1995 Dec 15;123(12):897–903.
178. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, etal. Interferon
alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis
C.Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485–92.
179. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al.
Peginterferon and ribavirin treatment in African American and Caucasian American patients
with hepatitis C genotype 1. Gastroenterology. 2006 Aug;131(2):470–7.
180. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, etal. A
variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with
impaired clearance of hepatitis C virus. Nat Genet. 2013 Feb;45(2):164–71.
181. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, etal. Complete
replication of hepatitis C virus in cell culture. Science. 2005 Jul 22;309(5734):623–6.
182. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R.Replication of sub-
genomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999 Jul 2;285(5424):110–3.
183. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of
infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005
Jul;11(7):791–6.
184. Bartenschlager R, Lohmann V, Penin F.The molecular and structural basis of advanced anti-
viral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013 Jul;11(7):482–96.
185. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, etal. Nonstructural pro-
tein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat. 2011 May;18(5):305–15.
186. Lindenbach BD, Rice CM.The ins and outs of hepatitis C virus entry and assembly. Nat Rev
Microbiol. 2013 Oct;11(10):688–700.
187. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, etal.
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011
Jun 23;364(25):2405–16.
188. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, etal. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195–206.
189. Halfon P, Sarrazin C.Future treatment of chronic hepatitis C with direct acting antivirals: is
resistance important? Liver Int. 2012 Feb;32(Suppl 1):79–87.
190. Goldenberg MM.Pharmaceutical approval update. P T. 2014 Feb;39(2):112–8.
191. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, etal. Once-daily simeprevir
(TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C:
the randomized PILLAR study. Hepatology. 2013 Dec;58(6):1918–29.
6
Chronic Hepatitis C
https://t.me/medicina_free
200
192. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, etal. Simeprevir increases rate
of sustained virologic response among treatment-experienced patients with HCV genotype-1
infection: a phase IIb trial. Gastroenterology. 2014 Feb;146(2):430–41.
193. Lawitz E, Gane EJ.Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl
J Med. 2013 Aug 15;369(7):678–9.
194. Pawlotsky JM.New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-
HCV drug development. Semin Liver Dis. 2014 Feb;34(1):22–9.
195. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, etal. Small
molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their
target: insights into compound modes of action. J Virol. 2011 Jul;85(13):6353–68.
196. Bhatia HK, Singh H, Grewal N, Natt NK.Sofosbuvir: a novel treatment option for chronic
hepatitis C infection. J Pharmacol Pharmacother. 2014 Oct;5(4):278–84.
197. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, etal. Ledipasvir and sofosbuvir
for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889–98.
198. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir
and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015 Dec
31;373(27):2599–607.
199. Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, etal. Ledipasvir/
sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a
pairwise meta-analysis. J Gastroenterol Hepatol. 2017 Apr;32(4):749–55.
200. Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, et al.
Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing,
and treating hepatitis C virus infection. Hepatology. 2019 Dec 9;71(2):686–721.
201. Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactiva-
tion among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017
Jul;66(1):27–36.
202. Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G, etal. Hepatitis C virus
p7 is critical for capsid assembly and envelopment. PLoS Pathogens. 2013;9(5):e1003355.
203. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F.Impact of hepatitis C
on health related quality of life: a systematic review and quantitative assessment. Hepatology.
2005 Apr;41(4):790–800.
204. Alberti A.Impact of a sustained virological response on the long-term outcome of hepatitis
C.Liver Int. 2011 Jan;31(Suppl 1):18–22.
205. Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, etal. Peg-IFNalpha/
ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobuline-
mia vasculitis: results at week 24. Ann Rheum Dis. 2014 May;73(5):831–7.
206. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al.
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C
virus-infected patients. Autoimmun Rev. 2011 Jun;10(8):444–54.
207. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary
porphyrin level and disappearance of skin lesions after successful interferon therapy in
a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol. 1995
Feb;22(2):249–50.
208. Sheikh MY, Wright RA, Burruss JB.Dramatic resolution of skin lesions associated with por-
phyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C.Dig Dis
Sci. 1998 Mar;43(3):529–33.
209. Furuta M, Kaito M, Gabazza E, Fujita N, Ishida S, Tamaki S, et al. Ineffective interferon
treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient
decrease in HCV RNA levels. J Gastroenterol. 2000;35(1):60–2.
210. Azim J, McCurdy H, Moseley RH.Porphyria cutanea tarda as a complication of therapy for
chronic hepatitis C.World J Gastroenterol WJG. 2008 Oct 14;14(38):5913–5.
211. Jessner W, Der-Petrossian M, Christiansen L, Maier H, Steindl-Munda P, Gangl A,
et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis
C.Hepatology. 2002 Nov;36(5):1301–2.
N. V. Bergasa
https://t.me/medicina_free
201
212. Singal AK, Venkata KVR, Jampana S, Islam FU, Anderson KE. Hepatitis C treatment in
patients with porphyria cutanea tarda. Am J Med Sci. 2017 Jun;353(6):523–8.
213. Ferraccioli GF, Salaf F, De Vita S, Casatta L, Avellini C, Carotti M, etal. Interferon alpha-2
(IFN alpha 2) increases lacrimal and salivary function in Sjogren’s syndrome patients.
Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol. 1996
Jul-Aug;14(4):367–71.
214. Areias J, Velho GC, Cerqueira R, Barbedo C, Amaral B, Sanches M, et al. Lichen planus
and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J
Gastroenterol Hepatol. 1996 Aug;8(8):825–8.
215. Grossmann Sde M, Teixeira R, de Aguiar MC, do Carmo MA. Exacerbation of oral lichen
planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Eur J Gastroenterol Hepatol. 2008 Jul;20(7):702–6.
216. Misaka K, Kishimoto T, Kawahigashi Y, Sata M, Nagao Y. Use of direct-acting antivirals
for the treatment of hepatitis C virus-associated Oral lichen planus: a case report. Case Rep
Gastroenterol. 2016 Sep–Dec;10(3):617–22.
217. Nagao Y, Nakasone K, Maeshiro T, Nishida N, Kimura K, Kawahigashi Y, etal. Successful
treatment of oral lichen planus with direct-acting antiviral agents after liver transplantation
for hepatitis C virus-associated hepatocellular carcinoma. Case Rep Gastroenterol. 2017
Sep-Dec;11(3):701–10.
218. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, etal. Progression
of liver brosis in patients with chronic hepatitis C after orthotopic liver transplantation.
Transplantation. 2003 Nov 27;76(10):1487–91.
219. Samonakis DN, Germani G, Burroughs AK.Immunosuppression and HCV recurrence after
liver transplantation. J Hepatol. 2012 Apr;56(4):973–83.
220. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of
clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation.
Hepatology. 2000 Oct;32(4 Pt 1):852–8.
221. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, et al. Timing and
severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury.
Transplantation. 1998 May 15;65(9):1178–82.
222. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recur-
rent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology. 1996
May;23(5):971–6.
223. Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JY.Cholestatic hepatitis leading to hepatic
failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology. 1994
Jan;106(1):248–51.
224. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al.
Immunosuppression and donor age with respect to severity of HCV recurrence after liver
transplantation. Liver Transpl. 2005 Apr;11(4):386–95.
225. Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, etal. Clinical
outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gra-
dient. Transpl Int. 2009 Feb;22(2):172–81.
226. Vinaixa C, Rubin A, Aguilera V, Berenguer M.Recurrence of hepatitis C after liver transplan-
tation. Ann Gastroenterol. 2013;26(4):304–13.
227. Chen T, Terrault NA.Perspectives on treating hepatitis C infection in the liver transplantation
setting. Curr Opin Organ Transplant. 2016 Apr;21(2):111–9.
228. Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, etal. Direct-acting antiviral
agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection:
systematic review and meta-analysis. Transpl Infect Dis. 2019 Apr;21(2):e13047.
6 Chronic Hepatitis C
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана